PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential

被引:69
|
作者
Yang, Tianrui [1 ]
Kong, Ziren [1 ]
Ma, Wenbin [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Neurosurg, Beijing, Peoples R China
关键词
Checkpoint inhibitor; glioblastoma; PD-1; PD-L1; immunotherapy; TUMOR MUTATIONAL BURDEN; LIGAND; EXPRESSION; COMBINED NIVOLUMAB; IPILIMUMAB; ANTI-PD-1; PEMBROLIZUMAB; MANAGEMENT; BLOCKADE; SURVIVAL; IMMUNOTHERAPY;
D O I
10.1080/21645515.2020.1782692
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Immune checkpoint inhibitors (CIs) have changed the landscape of tumor immunotherapy. Glioblastoma (GBM) remains the most common primary malignant brain tumor in adults and has a very poor prognosis. Due to the high invasiveness and aggressiveness of GBM, there is considerable interest in programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) treatment. However, the immunosuppressive and immune-privileged characteristics of GBM limit the efficacy of CIs. While clinical studies of CI monotherapies have shown unsatisfactory survival benefits, new treatment strategies have received attention. Multiple clinical studies have focused on combination of standard therapy (temozolomide, radiotherapy), targeted therapy and other immunotherapies, and some have reported results. Here, we reviewed recent clinical trials of anti-PD-1/PD-L1 monotherapy, studies with neoadjuvant strategies, and preclinical and clinical studies of combination immunotherapies for GBM. The preliminary clinical reports in certain subsets of patients with hypermutated or mismatch repair system deficiency GBM are also discussed.
引用
收藏
页码:546 / 553
页数:8
相关论文
共 50 条
  • [1] Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
    Wang, Xin
    Guo, Gaochao
    Guan, Hui
    Yu, Yang
    Lu, Jie
    Yu, Jinming
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (1)
  • [2] Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
    Xin Wang
    Gaochao Guo
    Hui Guan
    Yang Yu
    Jie Lu
    Jinming Yu
    [J]. Journal of Experimental & Clinical Cancer Research, 38
  • [3] PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review
    Caccese, Mario
    Indraccolo, Stefano
    Zagonel, Vittorina
    Lombardi, Giuseppe
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 135 : 128 - 134
  • [4] Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint
    Magiera-Mularz, Katarzyna
    Skalniak, Lukasz
    Zak, Krzysztof M.
    Musielak, Bogdan
    Rudzinska-Szostak, Ewa
    Berlicki, Lukasz
    Kocik, Justyna
    Grudnik, Przemyslaw
    Sala, Dominik
    Zarganes-Tzitzikas, Tryfon
    Shaabani, Shabnam
    Doemling, Alexander
    Dubin, Grzegorz
    Holak, Tad A.
    [J]. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2017, 56 (44) : 13732 - 13735
  • [5] Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers
    Duruisseaux, Michael
    Rouquette, Isabelle
    Adam, Julien
    Cortot, Alexis
    Cazes, Aurelie
    Gibault, Laure
    Damotte, Diane
    Lantuejoul, Sylvie
    [J]. ANNALES DE PATHOLOGIE, 2017, 37 (01) : 61 - 78
  • [6] Neoadjuvant PD-1/PD-L1 Immune Checkpoint Inhibitors in Solid Tumors
    Zhao, S.
    Li, X.
    Wang, S.
    Wang, Y.
    Huang, D.
    Da, Y.
    Song, Z.
    Chen, J.
    Manegold, C.
    Peng, L.
    Xu, S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S651 - S651
  • [7] Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
    Iosune Baraibar
    Ignacio Melero
    Mariano Ponz-Sarvise
    Eduardo Castanon
    [J]. Drug Safety, 2019, 42 : 281 - 294
  • [8] Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
    Baraibar, Iosune
    Melero, Ignacio
    Ponz-Sarvise, Mariano
    Castanon, Eduardo
    [J]. DRUG SAFETY, 2019, 42 (02) : 281 - 294
  • [9] Pyrazolones as inhibitors of immune checkpoint blocking the PD-1/PD-L1 interaction
    Le Biannic, Raphael
    Magnez, Romain
    Klupsch, Frederique
    Leleu-Chavain, Natascha
    Thiroux, Bryan
    Tardy, Morgane
    El Bouazzati, Hassiba
    Dezitter, Xavier
    Renault, Nicolas
    Vergoten, Gerard
    Bailly, Christian
    Quesnel, Bruno
    Thuru, Xavier
    Millet, Regis
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 236
  • [10] PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy
    Dermani, Fatemeh K.
    Samadi, Pouria
    Rahmani, Golebagh
    Kohlan, Alisa K.
    Najafi, Rezvan
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (02) : 1313 - 1325